botensilimab,balstilimab
agenus
our phase 1 trial of bot/bal was in heavily pre-treated patients, with a median of 4 prior lines of therapy. 34% of patients had previously received #immunotherapy and failed to respond. #esmogi
Our goal is to treat cancers with novel combinations using our unique portfolio of checkpoint antibodies, tumor microenvironment modifiers, vaccines & adjuvants